Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 May 1;24(5):508–517. doi: 10.5551/jat.36368

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

2017 Japan Atherosclerosis Society

This article is distributed under the terms of the latest version of CC BY-NC-SA defined by the Creative Commons Attribution License.http://creativecommons.org/licenses/by-nc-sa/3.0/

PMC Copyright notice

Fig. 4. — Cell hypertrophy of cardiomyocytes induced by endothelin-1 (ET-1) was inhibited by pre-treatment with fenofibrate. (A) To assess cellular hypertrophy, the cell size of cardiomyocytes was observed using Confocal Immunofluorescence study. ET-1 significantly increased the cell size of cardiomyocytes (upper right panel), compared to that of the control group (upper left panel); however, fenofibrate inhibited ET-1-induced cellular hypertrophy (lower left panel). In addition, the small interfering RNA (siRNA) of peroxisome proliferator-activated receptor α (PPARα), instead of Negative Contral (NC) siRNA, abolished the effects of fenofibrate (lower middle and right panels). (B) Quantitative results of the cell surface area of cardiomyocytes treated with fenofibrate, PPARα siRNA, or NC siRNA in response to ET-1 for 48 hours (n ≧ 10 cells per experimental group). Results are representative of three independent experiments.